Efficacy and Safety of IDegAsp Versus BIAsp 30, Both Twice Daily, in Elderly Patients with Type 2 Diabetes: Post Hoc Analysis of Two Phase 3 Randomized Controlled BOOST Trials.

Saved in:
Bibliographic Details
Title: Efficacy and Safety of IDegAsp Versus BIAsp 30, Both Twice Daily, in Elderly Patients with Type 2 Diabetes: Post Hoc Analysis of Two Phase 3 Randomized Controlled BOOST Trials.
Authors: Fulcher, Greg1 greg.fulcher@sydney.edu.au, Mehta, Roopa2, Fita, Edmond G.3, Ekelund, Magnus3, Bain, Stephen C.4
Source: Diabetes Therapy. Feb2019, Vol. 10 Issue 1, p107-118. 12p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:18696953
DOI:10.1007/s13300-018-0531-0